Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multi-center, global, Phase III study to assess the
efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab
monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for
unresectable HCC. The patients cannot be eligible for locoregional therapy.